Developer docs
API playgroundTry for free, no card

Search company profiles

Solve FSHD

Full company profile

uuid0007m4l

Namestring
Solve FSHD
Legal namestring
SOLVE FSHD Holdings Ltd.
Websiteurl
solvefshd.com
Company typeenum
Private
Founded yearint
2022
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersVancouver, Canada
HQ citystring
Vancouver
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture philanthropy, rare disease funding, FSHD therapeutics, biotech investment, muscular dystrophy research
Industry1 code
PRIMARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
NAICS code3 codes
  • Grantmaking Foundations813211
  • Voluntary Health Organizations813212
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Venture Philanthropy / FSHD Disease Research Funding
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Venture Philanthropy / Charitable Grant Funding
TypeLicensing Royalties
Description

SOLVE FSHD operates as a venture philanthropy organization funded by the Wilson family's $100 million USD commitment. The organization deploys capital through grants to academic researchers (up to $300,000 USD per grant, max 2 years, max 10% overhead), direct equity investments in biotech companies (e.g., $3M to Armatus Bio, up to $10M to Vita Therapeutics, $1M to miRecule), strategic co-development collaborations (Modalis, Transcripta Bio), and industry sponsorships of the XPRIZE Healthspan FSHD Bonus Prize. The organization does not generate revenue from product sales; its 'returns' are measured in therapeutic outcomes and patient impact rather than financial returns.

solvefshd.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Operations, Personnel, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

SOLVE FSHD is a venture philanthropy organization that accelerates the development of treatments for facioscapulohumeral muscular dystrophy (FSHD) by funding and co-developing therapeutic programs. It deploys a competitive academic grant program (up to $300,000 USD per award over two years) and direct strategic investments into biotech and biopharma partners working on DUX4-targeted therapies, biomarkers, natural history studies, and clinical outcome validation. Its product is the funded portfolio of therapeutic programs and the convening infrastructure (FSHD Industry Collaborative, $10M FSHD Bonus Prize via XPRIZE Healthspan) that aims to deliver a cure by December 31, 2027.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Grant funding of ~$571,000 awarded across two projects in 2025 to validate biomarker assays and clinical outcome frameworks for FSHD, with recipients at Radboud University and Newcastle University.
+3 more records
Product overview1 text field

Solve FSHD is a venture philanthropy organization rather than a traditional product company. The organization functions as a catalytic funding entity that identifies, funds, and accelerates promising therapeutic programs for Facioscapulohumeral Muscular Dystrophy (FSHD). The portfolio consists of strategic investments in external biotech and academic programs including: the MDL-103 CRISPR epigenome editing program (Modalis collaboration), ARM-201 AAV-delivered microRNA therapy (Armatus Bio investment), EPI-321 epigenetic therapy (Epic Bio investment), VTA-120 cell therapy (Vita Therapeutics investment), MC-DX4 antibody-RNA conjugate (miRecule investment), and AI-driven drug screening (Transcripta Bio collaboration). Additionally, the organization operates a grants program supporting biomarker research and clinical outcome validation at academic institutions. The interconnected portfolio is unified by the common goal of developing disease-modifying treatments that target the genetic cause of FSHD (DUX4 gene suppression or muscle regeneration) with a target solve date of December 31, 2027.

Product and service4 records
1FSHD Research Funding Program
CategoryCompetitive Research Grant Program
Description

Annual competitive grant program offering up to $300,000 USD per award (maximum 10% overhead, up to 2 years) to academic investigators conducting FSHD biomarker discovery, natural history studies, clinical outcome validation, and pre-clinical therapy development. Open to university and research hospital PIs globally.

2XPRIZE Healthspan FSHD Bonus Prize
CategoryInnovation Prize / Catalytic Competition
Description

Global $10 million milestone-prize competition co-sponsored by SOLVE FSHD as part of XPRIZE Healthspan, awarding eight $250,000 interim prizes by June 2025 and an $8 million grand prize for teams completing a clinical trial that demonstrates significant FSHD treatment advancements. Open to global teams.

3FSHD Patient Resource Network
CategoryPatient Advocacy and Resource Coordination
Description

Curated network connecting FSHD patients and families to patient advocacy organizations (FSHD Society, FSHD Global Research Foundation, FSHD Canada Foundation, MDA) for information, guidance, advocacy, direct support, registry participation, and clinical trial access.

4FSHD Industry Collaborative
CategoryIndustry Convening / Multi-Stakeholder Collaborative
Description

Multi-stakeholder industry collaborative co-organized by SOLVE FSHD with the FSHD Society and FSHD Clinical Trial Research Network and founding biopharma sponsors Sanofi, Fulcrum Therapeutics, and Scholar Rock to improve FSHD clinical trial design, execution, and evaluation and unify regulatory narratives.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership17 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-08
Description

The FSHD Society, SOLVE FSHD, and the FSHD Clinical Trial Research Network jointly launched the FSHD Industry Collaborative, a multi-stakeholder initiative to improve how FSHD clinical trials are designed, executed, and evaluated. The collaborative brings together biopharma companies, academic experts, and technology partners.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-08
Description

Partner in the FSHD Industry Collaborative alongside the FSHD Society and SOLVE FSHD, focused on improving the design, execution, and evaluation of FSHD clinical trials. The CTRN provides clinical research infrastructure and expertise.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-08
Description

Sanofi is a key sponsor of the FSHD Industry Collaborative, a multi-stakeholder initiative co-organized by the FSHD Society, SOLVE FSHD, and the FSHD CTRN to improve FSHD clinical trial design, execution, and evaluation. Sanofi joins Fulcrum Therapeutics and Scholar Rock as founding industry sponsors.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-08
Description

Fulcrum Therapeutics is a key sponsor of the FSHD Industry Collaborative. The company is focused on developing therapies for rare diseases, including FSHD, and participates in the collaborative to help improve clinical trial design and reduce drug development risk.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-08
Description

Scholar Rock is a key sponsor of the FSHD Industry Collaborative. The company is focused on developing therapies for serious diseases, including neuromuscular conditions, and participates in the collaborative to improve FSHD clinical trial outcomes.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-09
Description

SOLVE FSHD and Modalis announced a strategic collaboration to develop MDL-103, an innovative CRISPR-based epigenome editing treatment for FSHD using Modalis's proprietary CRISPR-GNDM technology to continuously suppress DUX4 gene expression. SOLVE FSHD provides strategic funding to support the MDL-103 program's advancement toward clinical trials.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-04-27
Description

Prof. Nicol Voermans from Radboud University Medical Center was selected as a grant recipient from SOLVE FSHD's 2025 Request for Proposals, receiving approximately $571,000 combined funding across two projects to validate biomarker assays and clinical outcome frameworks for FSHD.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-04-27
Description

Prof. Dr. Giorgio Tasca and Dr. Robert Muni Lofra from Newcastle University were selected as grant recipients from SOLVE FSHD's 2025 Request for Proposals, receiving approximately $571,000 combined funding to validate biomarker assays and clinical outcome frameworks for FSHD.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-03-25
Description

SOLVE FSHD entered a strategic collaboration with Transcripta Bio to leverage its AI-driven drug screening platform to identify and develop therapeutic candidates for FSHD. The project analyzes approved and late-stage clinical compound libraries in FSHD cell lines targeting fibro-adipogenic progenitor cells, representing a significant step in drug repurposing for FSHD.

10SOLVE FSHD 2023 Grant Recipients (4 Collaborative Projects)
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-07-11
Description

SOLVE FSHD awarded grants totaling USD $1.4M to four new collaborative research projects addressing critical gaps in FSHD therapeutics, biology, and/or biomarkers. Recipients represent relationships formed between academic and industry researchers during SOLVE FSHD's inaugural conference in Whistler, British Columbia.

solvefshd.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-03-08
Description

SOLVE FSHD financially supported the FSHD Canada Foundation's strategic investment of US$1.2M in biomarker grant funding to facilitate biomarker research in FSHD. The collaboration funded four projects including circulating biomarkers (Prof. Enzo Ricci and Dr. Giorgio Tasca), AI analysis for serum biomarkers (IMPROVE FSHD), UNDERSTAND FSHD2 natural history study (Dr. Sabrina Sacconi), and circulating biomarkers (Dr. Yi-Wen Chen).

Strategic tierCoreTypeStrategic or Co-development Partner
Description

FSHD Society is a key patient advocacy partner in the FSHD Industry Collaborative and a co-organizer of the FSHD Industry Collaborative alongside SOLVE FSHD and the FSHD CTRN. The organization provides information, guidance, advocacy, direct support, and access to clinical trials for the FSHD patient community.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

FSHD Global Research Foundation is listed as a partner organization providing information, guidance, advocacy, and direct support to the FSHD patient community. It is part of SOLVE FSHD's patient resource network.

14Michael Kyba (University of Minnesota)
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Michael Kyba serves on SOLVE FSHD's Scientific Advisory Board. He is Carrie Ramey CCRF Endowed Professor of Pediatrics at the University of Minnesota, where he investigates molecular mechanisms underlying DUX4 function and runs an active drug discovery program around DUX4 and FSHD.

solvefshd.com
15Lawrence Korngut (Calgary Neuromuscular Program)
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Lawrence Korngut serves on SOLVE FSHD's Scientific Advisory Board. He is a Neuromuscular Neurologist and former Director of the Calgary Neuromuscular Program and Calgary ALS Clinic. His team has conducted over 90 neuromuscular disease clinical trials and he is National Principal Investigator of the Canadian Neuromuscular Disease Registry.

solvefshd.com
16Peter Zammit (King's College London)
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Peter Zammit serves on SOLVE FSHD's Scientific Advisory Board. He is Professor of Cell Biology at King's College London and his contributions to FSHD include devising biomarkers (suppression of PAX7 target genes), quantifying muscle regeneration, and defining mitochondrial/metabolic dysfunction in FSHD.

solvefshd.com
17Giorgio Tasca (Newcastle University)
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Giorgio Tasca serves on SOLVE FSHD's Scientific Advisory Board. He is Clinical Professor of Neuromuscular Science at the John Walton Muscular Dystrophy Research Centre, Newcastle University, UK. His research focuses on muscle imaging in muscular dystrophies and molecular mechanisms and biomarkers in FSHD.

solvefshd.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

The ALS Association is a large incumbent patient advocacy organization funding ALS research, with biotech partnerships and clinical-trial infrastructure. Broader in scope than Solve FSHD but shares the playbook of combining patient advocacy, research grants, and industry collaboration.

TypeDirect peer
Description

The FSHD Society is the leading FSHD-specific patient advocacy organization and a core partner of Solve FSHD in the FSHD Industry Collaborative. Comparable FSHD focus, but operates primarily as an advocacy/registry/education body rather than a venture philanthropy grantmaker.

TypeDirect peer
Description

PPMD is a patient-founded nonprofit focused on Duchenne muscular dystrophy that funds research, drug development, and regulatory engagement — operating with a similar venture philanthropy / advocacy hybrid model on an adjacent muscular dystrophy indication.

TypeBroad incumbent
Description

MDA is the largest U.S. advocacy and research-funding organization for muscular dystrophy broadly, including FSHD. Larger and more diversified than Solve FSHD, with overlapping mission focus on FSHD research funding and patient support, but covers multiple disease areas.

5SMA Foundation
TypeDirect peer
Description

Spinal Muscular Atrophy Foundation is a disease-specific venture philanthropy organization funding SMA therapeutics R&D and biomarkers. Solve FSHD board member Karen Chen is SMA Foundation's CEO, highlighting the close operational and strategic parallels between the two organizations.

6Friedreich's Ataxia Research Alliance
TypeDirect peer
Description

FARA is a single-disease research foundation that funds academic and biotech drug development for Friedreich's ataxia using a venture philanthropy model. Closely comparable mission, funding mechanism, and biotech partnership playbook to Solve FSHD.

TypeDirect peer
Description

n-Lorem applies a venture philanthropy model to develop ASO therapies for nano-rare patients, and is itself a Solve FSHD grantee ($1M+ for FSHD2). Direct structural and operational comparison to Solve FSHD's grantmaking + biotech-investment playbook.

TypeDirect peer
Description

The Cystic Fibrosis Foundation pioneered the venture philanthropy model that Solve FSHD now uses — funding academic research and biotech drug development (including the program that became Vertex's Trikafta) toward curative therapies for a single rare disease. Highly comparable structure, capital deployment strategy, and mission framing.

TypeRegional player
Description

FSHD Canada Foundation is a Canadian patient organization and Solve FSHD partner that has deployed $1.2M of biomarker grant funding. Similar disease focus but smaller scale and primarily regional (Canada) compared to Solve FSHD's global mandate.

TypeRegional player
Description

FSHD Global is an Australia-based patient advocacy and research-funding organization focused on FSHD. Geographically complementary rather than directly competing with Solve FSHD's Vancouver-based global operations.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment7 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Solve FSHD

Venture Philanthropy / FSHD Disease Research Fundingsolvefshd.com

Solve FSHD firmographics

Firmographics
Name
Solve FSHD
Legal name
SOLVE FSHD Holdings Ltd.
Website
https://solvefshd.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Solve FSHD industry classification

Industry
Product category
Venture Philanthropy / FSHD Disease Research Funding
NAICS
Grantmaking Foundations (813211), Voluntary Health Organizations (813212), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking

Keywords

  • Venture philanthropy
  • Rare disease funding
  • FSHD therapeutics
  • Biotech investment
  • Muscular dystrophy research

Where Solve FSHD is headquartered

Location

Headquarters

HQ city
Vancouver
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Solve FSHD business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Operations, Personnel, Marketing or Sales, Others

Revenue model

  1. Venture Philanthropy / Charitable Grant Funding: SOLVE FSHD operates as a venture philanthropy organization funded by the Wilson family's $100 million USD commitment. The organization deploys capital through grants to academic researchers (up to $300,000 USD per grant, max 2 years, max 10% overhead), direct equity investments in biotech companies (e.g., $3M to Armatus Bio, up to $10M to Vita Therapeutics, $1M to miRecule), strategic co-development collaborations (Modalis, Transcripta Bio), and industry sponsorships of the XPRIZE Healthspan FSHD Bonus Prize. The organization does not generate revenue from product sales; its 'returns' are measured in therapeutic outcomes and patient impact rather than financial returns.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Solve FSHD product offering

Product offering

Core offering

SOLVE FSHD is a venture philanthropy organization that accelerates the development of treatments for facioscapulohumeral muscular dystrophy (FSHD) by funding and co-developing therapeutic programs. It deploys a competitive academic grant program (up to $300,000 USD per award over two years) and direct strategic investments into biotech and biopharma partners working on DUX4-targeted therapies, biomarkers, natural history studies, and clinical outcome validation. Its product is the funded portfolio of therapeutic programs and the convening infrastructure (FSHD Industry Collaborative, $10M FSHD Bonus Prize via XPRIZE Healthspan) that aims to deliver a cure by December 31, 2027.

Product overview

Solve FSHD is a venture philanthropy organization rather than a traditional product company. The organization functions as a catalytic funding entity that identifies, funds, and accelerates promising therapeutic programs for Facioscapulohumeral Muscular Dystrophy (FSHD). The portfolio consists of strategic investments in external biotech and academic programs including: the MDL-103 CRISPR epigenome editing program (Modalis collaboration), ARM-201 AAV-delivered microRNA therapy (Armatus Bio investment), EPI-321 epigenetic therapy (Epic Bio investment), VTA-120 cell therapy (Vita Therapeutics investment), MC-DX4 antibody-RNA conjugate (miRecule investment), and AI-driven drug screening (Transcripta Bio collaboration). Additionally, the organization operates a grants program supporting biomarker research and clinical outcome validation at academic institutions. The interconnected portfolio is unified by the common goal of developing disease-modifying treatments that target the genetic cause of FSHD (DUX4 gene suppression or muscle regeneration) with a target solve date of December 31, 2027.

Differentiator

Problem solved

Functional benefit

Products and services

  • FSHD Research Funding Program Annual competitive grant program offering up to $300,000 USD per award (maximum 10% overhead, up to 2 years) to academic investigators conducting FSHD biomarker discovery, natural history studies, clinical outcome validation, and pre-clinical therapy development. Open to university and research hospital PIs globally.
  • XPRIZE Healthspan FSHD Bonus Prize Global $10 million milestone-prize competition co-sponsored by SOLVE FSHD as part of XPRIZE Healthspan, awarding eight $250,000 interim prizes by June 2025 and an $8 million grand prize for teams completing a clinical trial that demonstrates significant FSHD treatment advancements. Open to global teams.
  • FSHD Patient Resource Network Curated network connecting FSHD patients and families to patient advocacy organizations (FSHD Society, FSHD Global Research Foundation, FSHD Canada Foundation, MDA) for information, guidance, advocacy, direct support, registry participation, and clinical trial access.
  • FSHD Industry Collaborative Multi-stakeholder industry collaborative co-organized by SOLVE FSHD with the FSHD Society and FSHD Clinical Trial Research Network and founding biopharma sponsors Sanofi, Fulcrum Therapeutics, and Scholar Rock to improve FSHD clinical trial design, execution, and evaluation and unify regulatory narratives.

Quantifiable outcome

  • Grant funding of ~$571,000 awarded across two projects in 2025 to validate biomarker assays and clinical outcome frameworks for FSHD, with recipients at Radboud University and Newcastle University.
  • +3 more outcomes

Companies that use Solve FSHD

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Solve FSHD technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

Solve FSHD partnerships and signals

Strategic signal

Partnerships

17 partnerships are on record, tiered core, major and minor.

  • FSHD SocietycoreStrategic or Co-development Partner · 8 April 2026The FSHD Society, SOLVE FSHD, and the FSHD Clinical Trial Research Network jointly launched the FSHD Industry Collaborative, a multi-stakeholder initiative to improve how FSHD clinical trials are designed, executed, and evaluated. The collaborative brings together biopharma companies, academic experts, and technology partners.
  • FSHD Clinical Trial Research Network (FSHD CTRN)coreStrategic or Co-development Partner · 8 April 2026Partner in the FSHD Industry Collaborative alongside the FSHD Society and SOLVE FSHD, focused on improving the design, execution, and evaluation of FSHD clinical trials. The CTRN provides clinical research infrastructure and expertise.
  • SanoficoreStrategic or Co-development Partner · 8 April 2026Sanofi is a key sponsor of the FSHD Industry Collaborative, a multi-stakeholder initiative co-organized by the FSHD Society, SOLVE FSHD, and the FSHD CTRN to improve FSHD clinical trial design, execution, and evaluation. Sanofi joins Fulcrum Therapeutics and Scholar Rock as founding industry sponsors.
  • Fulcrum TherapeuticscoreStrategic or Co-development Partner · 8 April 2026Fulcrum Therapeutics is a key sponsor of the FSHD Industry Collaborative. The company is focused on developing therapies for rare diseases, including FSHD, and participates in the collaborative to help improve clinical trial design and reduce drug development risk.
  • Scholar RockcoreStrategic or Co-development Partner · 8 April 2026Scholar Rock is a key sponsor of the FSHD Industry Collaborative. The company is focused on developing therapies for serious diseases, including neuromuscular conditions, and participates in the collaborative to improve FSHD clinical trial outcomes.
  • Modalis Therapeutics CorporationcoreStrategic or Co-development Partner · 9 June 2025SOLVE FSHD and Modalis announced a strategic collaboration to develop MDL-103, an innovative CRISPR-based epigenome editing treatment for FSHD using Modalis's proprietary CRISPR-GNDM technology to continuously suppress DUX4 gene expression. SOLVE FSHD provides strategic funding to support the MDL-103 program's advancement toward clinical trials.
  • Radboud University Medical Center (Prof. Nicol Voermans)majorStrategic or Co-development Partner · 27 April 2025Prof. Nicol Voermans from Radboud University Medical Center was selected as a grant recipient from SOLVE FSHD's 2025 Request for Proposals, receiving approximately $571,000 combined funding across two projects to validate biomarker assays and clinical outcome frameworks for FSHD.
  • Newcastle University (Prof. Dr. Giorgio Tasca and Dr. Robert Muni Lofra)majorStrategic or Co-development Partner · 27 April 2025Prof. Dr. Giorgio Tasca and Dr. Robert Muni Lofra from Newcastle University were selected as grant recipients from SOLVE FSHD's 2025 Request for Proposals, receiving approximately $571,000 combined funding to validate biomarker assays and clinical outcome frameworks for FSHD.
  • Transcripta BiomajorStrategic or Co-development Partner · 25 March 2025SOLVE FSHD entered a strategic collaboration with Transcripta Bio to leverage its AI-driven drug screening platform to identify and develop therapeutic candidates for FSHD. The project analyzes approved and late-stage clinical compound libraries in FSHD cell lines targeting fibro-adipogenic progenitor cells, representing a significant step in drug repurposing for FSHD.
  • SOLVE FSHD 2023 Grant Recipients (4 Collaborative Projects)majorStrategic or Co-development Partner · 11 July 2023SOLVE FSHD awarded grants totaling USD $1.4M to four new collaborative research projects addressing critical gaps in FSHD therapeutics, biology, and/or biomarkers. Recipients represent relationships formed between academic and industry researchers during SOLVE FSHD's inaugural conference in Whistler, British Columbia.
  • FSHD Canada FoundationmajorStrategic or Co-development Partner · 8 March 2022SOLVE FSHD financially supported the FSHD Canada Foundation's strategic investment of US$1.2M in biomarker grant funding to facilitate biomarker research in FSHD. The collaboration funded four projects including circulating biomarkers (Prof. Enzo Ricci and Dr. Giorgio Tasca), AI analysis for serum biomarkers (IMPROVE FSHD), UNDERSTAND FSHD2 natural history study (Dr. Sabrina Sacconi), and circulating biomarkers (Dr. Yi-Wen Chen).
  • FSHD SocietycoreStrategic or Co-development PartnerFSHD Society is a key patient advocacy partner in the FSHD Industry Collaborative and a co-organizer of the FSHD Industry Collaborative alongside SOLVE FSHD and the FSHD CTRN. The organization provides information, guidance, advocacy, direct support, and access to clinical trials for the FSHD patient community.
  • FSHD Global Research FoundationminorStrategic or Co-development PartnerFSHD Global Research Foundation is listed as a partner organization providing information, guidance, advocacy, and direct support to the FSHD patient community. It is part of SOLVE FSHD's patient resource network.
  • Michael Kyba (University of Minnesota)majorStrategic or Co-development PartnerMichael Kyba serves on SOLVE FSHD's Scientific Advisory Board. He is Carrie Ramey CCRF Endowed Professor of Pediatrics at the University of Minnesota, where he investigates molecular mechanisms underlying DUX4 function and runs an active drug discovery program around DUX4 and FSHD.
  • Lawrence Korngut (Calgary Neuromuscular Program)majorStrategic or Co-development PartnerLawrence Korngut serves on SOLVE FSHD's Scientific Advisory Board. He is a Neuromuscular Neurologist and former Director of the Calgary Neuromuscular Program and Calgary ALS Clinic. His team has conducted over 90 neuromuscular disease clinical trials and he is National Principal Investigator of the Canadian Neuromuscular Disease Registry.
  • Peter Zammit (King's College London)majorStrategic or Co-development PartnerPeter Zammit serves on SOLVE FSHD's Scientific Advisory Board. He is Professor of Cell Biology at King's College London and his contributions to FSHD include devising biomarkers (suppression of PAX7 target genes), quantifying muscle regeneration, and defining mitochondrial/metabolic dysfunction in FSHD.
  • Giorgio Tasca (Newcastle University)majorStrategic or Co-development PartnerGiorgio Tasca serves on SOLVE FSHD's Scientific Advisory Board. He is Clinical Professor of Neuromuscular Science at the John Walton Muscular Dystrophy Research Centre, Newcastle University, UK. His research focuses on muscle imaging in muscular dystrophies and molecular mechanisms and biomarkers in FSHD.

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Solve FSHD competitors and assessment

Company assessment

Broad incumbents

  • ALS Association: The ALS Association is a large incumbent patient advocacy organization funding ALS research, with biotech partnerships and clinical-trial infrastructure. Broader in scope than Solve FSHD but shares the playbook of combining patient advocacy, research grants, and industry collaboration.
  • Muscular Dystrophy Association: MDA is the largest U.S. advocacy and research-funding organization for muscular dystrophy broadly, including FSHD. Larger and more diversified than Solve FSHD, with overlapping mission focus on FSHD research funding and patient support, but covers multiple disease areas.

Direct peers

  • FSHD Society: The FSHD Society is the leading FSHD-specific patient advocacy organization and a core partner of Solve FSHD in the FSHD Industry Collaborative. Comparable FSHD focus, but operates primarily as an advocacy/registry/education body rather than a venture philanthropy grantmaker.
  • Parent Project Muscular Dystrophy: PPMD is a patient-founded nonprofit focused on Duchenne muscular dystrophy that funds research, drug development, and regulatory engagement — operating with a similar venture philanthropy / advocacy hybrid model on an adjacent muscular dystrophy indication.
  • SMA Foundation: Spinal Muscular Atrophy Foundation is a disease-specific venture philanthropy organization funding SMA therapeutics R&D and biomarkers. Solve FSHD board member Karen Chen is SMA Foundation's CEO, highlighting the close operational and strategic parallels between the two organizations.
  • Friedreich's Ataxia Research Alliance: FARA is a single-disease research foundation that funds academic and biotech drug development for Friedreich's ataxia using a venture philanthropy model. Closely comparable mission, funding mechanism, and biotech partnership playbook to Solve FSHD.
  • n-Lorem Foundation: n-Lorem applies a venture philanthropy model to develop ASO therapies for nano-rare patients, and is itself a Solve FSHD grantee ($1M+ for FSHD2). Direct structural and operational comparison to Solve FSHD's grantmaking + biotech-investment playbook.
  • Cystic Fibrosis Foundation: The Cystic Fibrosis Foundation pioneered the venture philanthropy model that Solve FSHD now uses — funding academic research and biotech drug development (including the program that became Vertex's Trikafta) toward curative therapies for a single rare disease. Highly comparable structure, capital deployment strategy, and mission framing.

Regional players

  • FSHD Canada Foundation: FSHD Canada Foundation is a Canadian patient organization and Solve FSHD partner that has deployed $1.2M of biomarker grant funding. Similar disease focus but smaller scale and primarily regional (Canada) compared to Solve FSHD's global mandate.
  • FSHD Global Research Foundation: FSHD Global is an Australia-based patient advocacy and research-funding organization focused on FSHD. Geographically complementary rather than directly competing with Solve FSHD's Vancouver-based global operations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Solve FSHD social profiles

Digital presence

Solve FSHD financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Solve FSHD leadership team

Management profile

Number of profiles

Profiles8 records

Solve FSHD funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Solve FSHD M&A and investment

M&A and investment

M&A

Investments7 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Solve FSHD

What does Solve FSHD do?

SOLVE FSHD is a venture philanthropy organization that accelerates the development of treatments for facioscapulohumeral muscular dystrophy (FSHD) by funding and co-developing therapeutic programs. It deploys a competitive academic grant program (up to $300,000 USD per award over two years) and direct strategic investments into biotech and biopharma partners working on DUX4-targeted therapies, biomarkers, natural history studies, and clinical outcome validation. Its product is the funded portfolio of therapeutic programs and the convening infrastructure (FSHD Industry Collaborative, $10M FSHD Bonus Prize via XPRIZE Healthspan) that aims to deliver a cure by December 31, 2027.

Is Solve FSHD a public or private company?

Solve FSHD is a private company. It is classified as family owned and is currently operating.

When was Solve FSHD founded?

Solve FSHD was founded in 2022. It employs 11 to 50 people.

Where is Solve FSHD based?

Solve FSHD is headquartered in Vancouver, Canada, in the North America region.

How does Solve FSHD make money?

One revenue line is on record: venture Philanthropy / Charitable Grant Funding.

Who are Solve FSHD's main competitors?

Broad incumbents on record are ALS Association and Muscular Dystrophy Association. Direct peers are FSHD Society, Parent Project Muscular Dystrophy, SMA Foundation, Friedreich's Ataxia Research Alliance, n-Lorem Foundation and Cystic Fibrosis Foundation. Regional players are FSHD Canada Foundation and FSHD Global Research Foundation.

Does Solve FSHD have an API?

No public API is recorded for Solve FSHD.

What industry is Solve FSHD in?

Solve FSHD's product category is Venture Philanthropy / FSHD Disease Research Funding. Its primary akta.pro industry code is BPAGAKAL, Health & Medical Research Grantmaking Foundations. Its NAICS code is 813211 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Financial PostSOLVE FSHD Portfolio Company Altay Therapeutics Closes $37 Million Series A Financing to Advance DX5057 for FSHDAltay Therapeutics closed a $37 million Series A financing co-led by Sound Bioventures and HealthCap. The funds will advance DX5057, an oral DUX4 inhibitor, through Phase 1 and a Phase 2 proof-of-concept trial. SOLVE FSHD had previously provided nearly $7 million in seed financing.FinancialContent Business PageSOLVE FSHD Portfolio Company Altay Therapeutics Closes $37 Million Series A Financing to Advance DX5057 for FSHDAltay Therapeutics closed a $37 million Series A financing co-led by Sound Bioventures and HealthCap. The funds will advance DX5057, an oral DUX4 inhibitor, through Phase 1 and Phase 2 trials for FSHD. SOLVE FSHD had provided nearly $7 million in seed support.FinancialContent Business PageSOLVE FSHD Accelerates Development of SFH-4090, a Novel DUX4 Inhibitor for FSHDSOLVE FSHD and Tanabe Pharma presented nonclinical data for SFH-4090, a DUX4-targeting ASO, at the World Muscle Society Congress 2026. The data show skeletal muscle concentrations 18 times higher than plasma after weekly subcutaneous dosing, with a half-life of about 16 days. The findings support continued development toward clinical trials for FSHD.Business Wire BlogSOLVE FSHD Accelerates Development of SFH-4090, a Novel DUX4 Inhibitor for FSHDSOLVE FSHD and Tanabe Pharma announced new nonclinical data for SFH-4090, a DUX4 inhibitor for FSHD, presented at the World Muscle Society Congress. The data show skeletal muscle concentrations 18 times higher than plasma after weekly subcutaneous dosing, with sustained exposure supporting clinical trial readiness.Financial PostSOLVE FSHD Announces Recent Grant Awards to Accelerate Treatments for Facioscapulohumeral Muscular DystrophySOLVE FSHD, a venture philanthropy organization, announced grant funding of approximately USD $571,000 awarded across two projects following its 2025 Request for Proposals, aimed at validating biomarker assays and clinical outcome frameworks for facioscapulohumeral muscular dystrophy. The recipients are Prof. Nicol Voermans from Radboud University Medical Center and Prof. Dr. Giorgio Tasca and Dr. Robert Muni Lofra from Newcastle University, selected from a competitive international pool of applicants. The organization, founded by lululemon founder Chip Wilson with a $100 million family commitment, stated the goal is to build an FSHD toolkit for use in clinical trials by academic and industry partners within the next few years.PR NewswireThe FSHD Society, SOLVE FSHD, and the FSHD CTRN Announce Launch of Industry Collaborative to Improve FSHD Clinical TrialsThe FSHD Society, SOLVE FSHD, and the FSHD Clinical Trial Research Network have launched the FSHD Industry Collaborative, a multi-stakeholder initiative to improve how facioscapulohumeral muscular dystrophy clinical trials are designed, executed, and evaluated. The collaborative brings together biopharma companies, academic experts, and technology partners to analyze biomarker and clinical data to reduce drug development risk and support unified regulatory narratives. Key sponsors include Sanofi, Fulcrum Therapeutics, and Scholar Rock, with initial work already underway and additional pharmaceutical companies being welcomed to participate.SolvefshdSOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular DystrophySOLVE FSHD and Modalis Therapeutics announced a collaboration to develop MDL-103, a CRISPR-based epigenome editing therapy for facioscapulohumeral muscular dystrophy. The therapy suppresses the DUX4 gene using Modalis's CRISPR-GNDM technology, with SOLVE FSHD providing strategic funding. The company aims to accelerate MDL-103 into clinical trials.Business Wire BlogSOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular DystrophySOLVE FSHD and Modalis announced a collaboration to develop a CRISPR-based epigenome editing therapy for facioscapulohumeral muscular dystrophy (FSHD). The therapy, MDL-103, uses Modalis's CRISPR-GNDM technology to suppress the DUX4 gene, with SOLVE FSHD providing strategic funding. The company aims to accelerate MDL-103 into clinical trials.SolvefshdSOLVE FSHD Announces $3 Million Investment in Armatus Bio to Advance Gene Therapy Program for FSHDSOLVE FSHD announced a $3 million investment in Armatus Bio to advance its ARM-201 gene therapy for facioscapulohumeral muscular dystrophy (FSHD). The therapy targets DUX4 expression and has completed a pre-IND meeting with the FDA. The funding will support IND-enabling activities for regulatory submission.citybizSOLVE FSHD Announces $3 Million Investment in Armatus BioSOLVE FSHD announced a $3 million investment in Armatus Bio to advance ARM-201, an AAV-delivered microRNA therapy targeting DUX4 in facioscapulohumeral muscular dystrophy. The funding will support IND-enabling activities, with a pre-IND meeting completed. The company aims to position the therapy for regulatory submission and clinical trials.